SCHEMBL3060871

SCHEMBL3060871

[CH2]Cc1cccc(S(=O)(=O)NC)c1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TNNI3K Q59H18 6/20 0.45
EGFR P00533 2/20 0.45
LMNA P02545 2/20 0.43
PTBP1 P26599 1/20 0.43
CYP4F2 P78329 1/20 0.43
CYP4A11 Q02928 1/20 0.43
CYP19A1 P11511 2/20 0.42
KMT2A Q03164 1/20 0.42
HTR6 P50406 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
POLB P06746 1/20 0.41
NQO2 P16083 1/20 0.41
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
IDH1 O75874 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12217548 0.84 KAT6A (0.49) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL5293352 0.82 IKBKB (0.48) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL22070843 0.82 L3MBTL1 (0.47) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL1014348 0.82 HTR6 (0.55) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL2462774 0.82 L3MBTL1 (0.47) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL10273897 0.81 KAT6A (0.51) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
Hydrochloric Acid SCHEMBL4636143 0.81 HTR6 (0.54) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL2242660 0.80 L3MBTL1 (0.61) L3MBTL1GAASMN1; SMN2TNNI3KEGFR
SCHEMBL2542290 0.79 ALDH1A1 (0.46) GAASMN1; SMN2CYP4F2CYP4A11HTR6
SCHEMBL18970321 0.79 TNNI3K (0.46) L3MBTL1GAASMN1; SMN2TNNI3KEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8551999-B2 Heterocyclic compound and pharmaceutical composition thereof OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-10-08 US disclosed
EP-2207773-B1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMA CO LTD (JP) 2012-07-11 EP disclosed
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-10-14 US disclosed
EP-2207773-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF Otsuka Pharmaceutical Co., Ltd. (JP) 2010-07-21 EP disclosed
WO-2009057811-A2 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261720-A1 HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF COL1A1, COL2A1, COL14A1 L3MBTL1 4015/4885GAA 4287/4885SMN1; SMN2 3814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.